Dicerna Pharmaceuticals Inc
F:DPL
Balance Sheet
Balance Sheet Decomposition
Dicerna Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Balance Sheet
Dicerna Pharmaceuticals Inc
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
23
|
4
|
47
|
26
|
56
|
21
|
69
|
54
|
153
|
126
|
|
| Cash Equivalents |
23
|
4
|
47
|
26
|
56
|
21
|
69
|
54
|
153
|
126
|
|
| Short-Term Investments |
0
|
0
|
0
|
70
|
39
|
25
|
45
|
248
|
196
|
443
|
|
| Total Receivables |
0
|
5
|
0
|
0
|
0
|
1
|
2
|
101
|
202
|
36
|
|
| Accounts Receivables |
0
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
2
|
1
|
2
|
1
|
3
|
2
|
5
|
14
|
|
| Total Current Assets |
23
|
9
|
49
|
97
|
96
|
48
|
119
|
406
|
556
|
619
|
|
| PP&E Net |
1
|
1
|
1
|
2
|
3
|
2
|
2
|
3
|
37
|
78
|
|
| PP&E Gross |
1
|
1
|
1
|
2
|
3
|
2
|
0
|
3
|
37
|
78
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
3
|
3
|
4
|
0
|
5
|
7
|
5
|
|
| Long-Term Investments |
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
2
|
1
|
1
|
1
|
1
|
4
|
11
|
|
| Total Assets |
25
N/A
|
10
-59%
|
50
+388%
|
104
+108%
|
100
-3%
|
51
-49%
|
121
+136%
|
409
+238%
|
597
+46%
|
708
+18%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
2
|
1
|
3
|
4
|
5
|
5
|
6
|
8
|
|
| Accrued Liabilities |
0
|
0
|
1
|
4
|
6
|
6
|
6
|
20
|
23
|
32
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
4
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
0
|
0
|
0
|
0
|
0
|
6
|
69
|
212
|
139
|
|
| Total Current Liabilities |
5
|
6
|
8
|
5
|
9
|
10
|
17
|
94
|
242
|
178
|
|
| Long-Term Debt |
9
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
0
|
1
|
0
|
0
|
0
|
3
|
114
|
204
|
392
|
|
| Total Liabilities |
15
N/A
|
11
-29%
|
9
-21%
|
5
-38%
|
9
+70%
|
10
+11%
|
20
+99%
|
208
+947%
|
445
+114%
|
570
+28%
|
|
| Equity | |||||||||||
| Common Stock |
60
|
64
|
110
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
51
|
65
|
86
|
133
|
196
|
256
|
316
|
405
|
525
|
638
|
|
| Additional Paid In Capital |
0
|
0
|
17
|
232
|
287
|
297
|
417
|
606
|
678
|
776
|
|
| Total Equity |
10
N/A
|
1
N/A
|
41
N/A
|
98
+138%
|
91
-7%
|
41
-55%
|
101
+145%
|
201
+99%
|
152
-24%
|
138
-9%
|
|
| Total Liabilities & Equity |
25
N/A
|
10
-59%
|
50
+388%
|
104
+108%
|
100
-3%
|
51
-49%
|
121
+136%
|
409
+238%
|
597
+46%
|
708
+18%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
11
|
11
|
11
|
18
|
21
|
21
|
52
|
68
|
72
|
76
|
|